MAPT and Alzheimer disease: Given that ⍺Syn pathology appears to contribute to disease progression in a sizeable proportion of AD patients there is concern that monotherapies targeting tau or Aβ in such patients will be of less benefit than in patients free of ⍺Syn pathology.